PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the appointment of Dr. Karen Smith, MD, PhD, MBA, LLM, as interim Chief Medical Officer (CMO), effective May 10, 2025. Dr. Smith, who has served on Context’s Board of Directors since 2024, will step into this dual role while the company conducts a search for a full-time CMO. She succeeds Dr. Claudio Dansky Ullmann, who is leaving the organization.
Dr. Smith brings over two decades of experience in biopharmaceuticals, including senior leadership positions at Jazz Pharmaceuticals, Allergan, AstraZeneca, and Bristol Myers Squibb. Her expertise spans drug development, from clinical trials to commercialization, making her a key asset in guiding Context’s therapeutic pipeline.
“As we take the next steps in advancing our pipeline, I am delighted to have Karen’s support and leadership,” said Martin Lehr, CEO of Context Therapeutics. “Karen’s experience in drug development will make her guidance invaluable through this transition. I am grateful to Claudio for his contributions to Context.”
Dr. Smith’s extensive expertise will ensure strategic continuity as Context progresses its clinical development programs. Her leadership marks a pivotal moment for the company as it continues to innovate in biopharmaceutical advancements.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.